SAB Biotherapeutics (SABS) Assets Average (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Assets Average came in at $210.6 million in Q1 2026, up 411.79% YoY from $41.2 million in Q1 2025, and up 18.25% on a QoQ basis from $178.1 million in Q4 2025.
SAB Biotherapeutics (SABS) Assets Average (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Assets Average data on file, last reported at $210.6 million in Q1 2026.
- Quarterly Assets Average rose 411.79% year-over-year to $210.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210.6 million (up 411.79% YoY) and the FY2025 annual result came in at $108.5 million, up 69.35% from the prior year.
- Assets Average advanced to $210.6 million in Q1 2026, from $178.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $210.6 million in Q1 2026 to a low of $31.9 million in Q3 2023.
- A 5-year average of $73.1 million and a median of $56.1 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average sank 52.18% — and 2026, when it jumped 411.79%.
- Tracing SABS's Assets Average over 5 years: stood at $51.7 million in 2022, then increased by 8.57% to $56.1 million in 2023, then decreased by 12.72% to $49.0 million in 2024, then surged by 263.56% to $178.1 million in 2025, then rose by 18.25% to $210.6 million in 2026.
- The last three Assets Average figures came in at $210.6 million (Q1 2026), $178.1 million (Q4 2025), and $106.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 243.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 243.34 Mn |
| Mar 31, 2026 | 210.64 Mn |
| Dec 31, 2025 | 178.13 Mn |
| Sep 30, 2025 | 106.79 Mn |
| Jun 30, 2025 | 34.12 Mn |
| Mar 31, 2025 | 41.16 Mn |
| Dec 31, 2024 | 49.00 Mn |
| Sep 30, 2024 | 57.84 Mn |
| Jun 30, 2024 | 66.63 Mn |
| Mar 31, 2024 | 77.66 Mn |
| Dec 31, 2023 | 56.14 Mn |
| Sep 30, 2023 | 31.89 Mn |
| Jun 30, 2023 | 39.06 Mn |
| Mar 31, 2023 | 46.79 Mn |
| Dec 31, 2022 | 51.71 Mn |
| Sep 30, 2022 | 55.96 Mn |
| Jun 30, 2022 | 63.95 Mn |
| Mar 31, 2022 | 74.81 Mn |
| Dec 31, 2021 | 99.03 Mn |
| Sep 30, 2021 | 117.01 Mn |